Liraglutide in Newly Onset Type 1 Diabetes.

Sponsor
Hvidovre University Hospital
Study ID
NCT01879917
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.

Key Dates

Start date
Feb 28, 2014
Status verified
Mar 2021
Primary completion
Aug 31, 2018
Completion
Aug 31, 2018

Study Design

Enrollment
65 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide
    1.8 mg
  • Placebo Comparator: Saline

Primary Outcome Measure

Beta-cell function [ Time Frame: 52 weeks ]

Related Studies